Dr. O'Brien is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4745 Ogletown Stanton Rd
Ste 220
Newark, DE 19713Phone+1 302-368-5515Fax+1 302-366-1240
Summary
- Gerald O'Brien, MD is a Pulmonology specialist located in Hockessin, DE. He has subspecialties including Critical Care Medicine and Pulmonary Vascular Medicine. Dr. O'Brien completed his medical education at Ponce Health Sciences University School of Medicine, his internship and residency in Internal Medicine at Christiana Care Health Services, and a fellowship in Pulmonary Disease and Critical Care Medicine at Temple University Hospital. Over his career, he has held multiple high-ranking positions, including Executive Director at Insmed and Vice President at Liquidia Technologies and Complexa. He was also the founding Medical Director for Lung Transplant program at Temple University as well as the former director of Pulmonary Hypertension and Interventional Pulmonary at ChristianaCare. Dr. O'Brien has numerous publications to his name in the realm of chronic obstructive pulmonary disease and pulmonary vascular disease. He has been involved in clinical trials related to pulmonary arterial hypertension and has been recognized with awards like Meaningful Use Stage 1 Certification and Top MD from Consumers Checkbook.
Education & Training
- Temple University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1993
- Sidney Kimmel Medical College at Thomas Jefferson University/Christiana Care Health ServicesResidency, Internal Medicine, 1984 - 1987
- Sidney Kimmel Medical College at Thomas Jefferson University/Christiana Care Health ServicesInternship, Internal Medicine, 1983 - 1984
- Ponce Health Sciences University School of MedicineClass of 1983
Certifications & Licensure
- DE State Medical License 2000 - 2025
- MD State Medical License 1990 - 2013
- PA State Medical License 1991 - 2006
- American Board of Internal Medicine Internal Medicine
- American Academy of Bronchology and Interventional pulmonologyInterventional pulmonology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Top MD Consumers Checkbook
Clinical Trials
- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
- Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- 14 citationsIntraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison StudiesThomas P. Lodise, Jingyi Li, H. Gandhi, Gerald O’Brien, Sanjay Sethi
International Journal of Chronic Obstructive Pulmonary Disease. 2020-11-11 - 4 citationsBenefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very s...Fernando J. Martinez, Brian J. Lipworth, Klaus F. Rabe, David Collier, Gary T. Ferguson
Respiratory Research. 2020-05-25 - 9 citationsRiociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study:Namita Sood, Alvaro Aranda, David Platt, Anneliese LaRose, Frank Kleinjung
Pulmonary Circulation. 2019-02-19
Journal Articles
- Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison StudiesThomas P Lodise,1 Jingyi Li,2 Hitesh N Gandhi,3 Gerald O’Brien,3 and Sanjay Sethi4, Int J Chron Obstruct Pulmon Dis., 11/11/2020
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: